Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.98% | 30.46% | 11.10% | -4.46% | 26.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.98% | 30.46% | 11.10% | -4.46% | 26.88% |
| Cost of Revenue | 21.50% | 37.79% | 28.20% | 11.32% | 37.37% |
| Gross Profit | 61.05% | 22.77% | -6.34% | -21.45% | 14.62% |
| SG&A Expenses | 40.62% | 20.56% | 22.78% | 5.92% | 30.02% |
| Depreciation & Amortization | 30.69% | 36.83% | -9.09% | -18.14% | -7.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.64% | 34.43% | 20.56% | 4.76% | 30.61% |
| Operating Income | 310.66% | -80.03% | -180.74% | -295.54% | -3,366.39% |
| Income Before Tax | 43.11% | -412.20% | -2,265.11% | 94.75% | 129.27% |
| Income Tax Expenses | 183.21% | 254.78% | -211.30% | 6.56% | -52.22% |
| Earnings from Continuing Operations | -17.18% | -4,517.98% | -542.81% | 145.15% | 142.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.18% | -4,517.98% | -542.81% | 145.15% | 142.89% |
| EBIT | 310.66% | -80.03% | -180.74% | -295.54% | -3,366.39% |
| EBITDA | 155.96% | 9.90% | -52.58% | -62.73% | -20.19% |
| EPS Basic | -16.25% | -4,700.00% | -554.29% | 145.95% | 144.26% |
| Normalized Basic EPS | 189.87% | -0.97% | -1,425.00% | -100.45% | -2,733.33% |
| EPS Diluted | -10.88% | -4,933.33% | -543.84% | 141.74% | 140.76% |
| Normalized Diluted EPS | 189.87% | -0.97% | -1,425.00% | -100.45% | -2,733.33% |
| Average Basic Shares Outstanding | -1.19% | -1.46% | -1.68% | -1.51% | -3.07% |
| Average Diluted Shares Outstanding | -1.07% | -1.46% | -1.68% | -1.08% | -2.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |